15 Nov 2017 07:00
For immediate release
15 November 2017
ABCAM PLC
("Abcam" or the "Company")
Result of AGM and Directorate Change
Abcam, a global leader in the supply of life science research tools, is pleased to announce that all resolutions put to its Annual General Meeting (the "AGM") held yesterday were duly passed.
On 11 October 2017, the Company announced that Murray Hennessey would relinquish his Non-Executive Chairman position and step down from the Board following the AGM. Accordingly, at today's meeting the Chairman proposed a motion to withdraw Resolution 6 (To re-elect Murray Hennessy as a Director). The motion was agreed and Resolution 6 was withdrawn and not put to the vote.
Following the AGM, Murray Hennessey stepped down as Chairman and as a Director of the Company and has been replaced as Interim Chairman by Louise Patten, an existing Non-Executive Director of the Company. Louise, who does not wish to be considered for the role, is leading the process to identify a new Chairman and has agreed to assume the role of Interim Chairman until such time that a permanent Chairman is appointed.
The Board thanks Murray for his contribution to the Company over the last six years and wish him well in the future.
For further information, please contact:
Abcam
+ 44 (0) 1223 696 000
Suzanne Smith, Chief Legal Officer and Company Secretary
J.P.Morgan Cazenove - Nominated Advisor & Corporate Broker
+ 44 (0) 20 7742 4000
James Mitford / Candelle Chong
FTI Consulting
+ 44 (0) 20 3727 1000
Ben Atwell / Brett Pollard / Natalie Garland-Collins
Notes for editors:
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use Abcam's affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.
By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.
Abcam's twelve locations are in the world's leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 130 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com and www.abcamplc.com
Forward looking statements
This announcement, including any information included or incorporated by reference in this announcement, may contain forward-looking statements (including words such as "believe", "expect", "estimate", "intend", "anticipate" and words of similar meaning) which are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Abcam Group. All statements other than statements of historical facts may be forward-looking statements and should not be treated as guarantees of future performance. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Abcam Group, and there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These forward-looking statements speak only as at the date of this announcement and accordingly undue reliance should not be placed on such statements. The Abcam Group does not assume any obligation to, and does not intend to, revise or update these forward-looking statements, except as required pursuant to applicable law.